InvestorsHub Logo
Followers 21
Posts 1996
Boards Moderated 0
Alias Born 11/26/2014

Re: Hank Kerchief post# 3320

Monday, 06/11/2018 10:25:47 AM

Monday, June 11, 2018 10:25:47 AM

Post# of 4163
Can look at rev projections for NMIBC refractory treatment in Loe's assessment. The brain and lung work currently are not priced in.

Bladder cancer-targeted PDT TLD-1433 is a major value driver in our model
http://67.212.93.22/research/content/20170905TLT%20final.pdf


So at this price we are at like 2013 year study levels. This one will break its range.